Martin J Boeree
Overview
Explore the profile of Martin J Boeree including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
3972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, et al.
Lancet Microbe
. 2025 Jan;
6(2):100952.
PMID: 39793592
Background: The broad use of bedaquiline and pretomanid as the mainstay of new regimens to combat tuberculosis is a risk due to increasing bedaquiline resistance. We aimed to assess the...
2.
Stemkens R, Lemson A, Koele S, Svensson E, Te Brake L, van Crevel R, et al.
J Antimicrob Chemother
. 2024 Oct;
79(12):3100-3108.
PMID: 39378281
Objectives: Clofazimine is a promising drug for the treatment of nontuberculous mycobacterial (NTM) diseases. Accumulation of clofazimine to reach steady-state plasma concentrations takes months. A loading dose may reduce the...
3.
van Arkel C, Storms I, Kurver L, Smeenk F, Wielders P, Hoefsloot W, et al.
J Infect
. 2024 Jun;
89(2):106200.
PMID: 38901573
Background: Susceptibility to respiratory infections increases with age. Diagnosing and treating tuberculosis in the elderly comes with the challenges of fewer specific symptoms and possibly more side effects of treatment....
4.
Zweijpfenning S, Aarnoutse R, Boeree M, Magis-Escurra C, Stemkens R, Geurts B, et al.
Chest
. 2023 Dec;
165(5):1082-1092.
PMID: 38040054
Background: Results of retrospective studies have suggested clofazimine as an alternative for rifampicin in the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). Research Question: Is a treatment regimen consisting...
5.
Stemkens R, de Jager V, Dawson R, Diacon A, Narunsky K, Padayachee S, et al.
Antimicrob Agents Chemother
. 2023 Sep;
67(10):e0068323.
PMID: 37768317
Accumulating evidence supports the use of higher doses of rifampicin for tuberculosis (TB) treatment. Rifampicin is a potent inducer of metabolic enzymes and drug transporters, resulting in clinically relevant drug...
6.
Boeree M, Heinrich N, Aarnoutse R
N Engl J Med
. 2023 Jun;
388(24):2297.
PMID: 37314715
No abstract available.
7.
Martinecz A, Boeree M, Diacon A, Dawson R, Hemez C, Aarnoutse R, et al.
PLoS Comput Biol
. 2023 Apr;
19(4):e1011000.
PMID: 37053266
Background: Antibiotic treatments are often associated with a late slowdown in bacterial killing. This separates the killing of bacteria into at least two distinct phases: a quick phase followed by...
8.
Susanto B, Svensson E, Te Brake L, Aarnoutse R, Boeree M, Simonsson U
Int J Antimicrob Agents
. 2023 Apr;
61(6):106813.
PMID: 37037318
Background: Higher doses of rifampicin for tuberculosis have been shown to improve early bactericidal activity (EBA) and at the same time increase the intolerability due to high exposure at the...
9.
Ayoun Alsoud R, Svensson R, Svensson E, Gillespie S, Boeree M, Diacon A, et al.
Front Pharmacol
. 2023 Mar;
14:1067295.
PMID: 36998606
Biomarkers are quantifiable characteristics of biological processes. In , common biomarkers used in clinical drug development are colony forming unit (CFU) and time-to-positivity (TTP) from sputum samples. This analysis aimed...
10.
Dominguez J, Boeree M, Cambau E, Chesov D, Conradie F, Cox V, et al.
Lancet Infect Dis
. 2023 Mar;
23(4):e122-e137.
PMID: 36868253
Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations...